Alaunos Therapeutics Receivables 2010-2025 | TCRT

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Alaunos Therapeutics receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Alaunos Therapeutics receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$81.3B
Zoetis (ZTS)	$67.7B
Daiichi Sankyo, - (DSNKY)	$46.4B
Takeda Pharmaceutical (TAK)	$46.1B
BeOne Medicines - (ONC)	$31.9B
Sandoz Group AG (SDZNY)	$26.1B
Summit Therapeutics (SMMT)	$21.3B
Merck (MKKGY)	$17.2B
Shionogi (SGIOY)	$14.6B
United Therapeutics (UTHR)	$13.7B
Neurocrine Biosciences (NBIX)	$13.1B
Orion OYJ (ORINY)	$11.7B
IPSEN (IPSEY)	$10.9B
Stevanato Group S.p.A (STVN)	$8B
Corcept Therapeutics (CORT)	$7.2B
Grifols, S.A (GRFS)	$6.9B
Ionis Pharmaceuticals (IONS)	$6.7B
Madrigal Pharmaceuticals (MDGL)	$6.6B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.4B
Hypermarcas (HYPMY)	$2.9B
Crinetics Pharmaceuticals (CRNX)	$2.9B
NewAmsterdam Pharma (NAMS)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.1B
Ocular Therapeutix (OCUL)	$1.9B
Endo (NDOI)	$1.8B
BioCryst Pharmaceuticals (BCRX)	$1.8B